Avastin in addition Folfox4 chemotherapy significantly extends survival in second-series metastatic colorectal cancer Genentech and Roche today announced a randomized Stage III research of Avastin in addition to the FOLFOX4 chemotherapy program , in comparison to FOLFOX4 only, in second-series metastatic colorectal cancer sufferers achieved its major endpoint of improving general survival. Outcomes from an interim evaluation demonstrated that sufferers getting Avastin plus FOLFOX4 acquired a 26 % decrease in the risk of loss of life, a hazard ratio of 0.74, in comparison to individuals who received FOLFOX4 alone articles on malegra dxt . Median survival for sufferers receiving FOLFOX4 in addition Avastin was 12.5 months, in comparison to 10.7 months for all those receiving FOLFOX4 alone, a 17 % improvement.
15 and Dec. 31 . Regarding to CMS spokesperson Tony Salters, about 10 percent to 15 percent of Medicare beneficiaries will change prescription drug plans through the enrollment period . UnitedHealth, Humana TO REDUCE Dual Eligibles Humana and UnitedHealth, the two largest companies of Medicare prescription medication plans, in 2008 most likely will lose several million dual eligibles mixed. UnitedHealth will eventually lose about 650,000 dual eligibles in 2008 because premiums for Medicare prescription drug programs offered by the business will exceed the price limit in 18 of 34 regional marketplaces, according to analysts. Humana shall lose about 500,000 dual eligibles in 2008 for the same cause, analysts stated .